Anti-proliferative action of silibinin on human colon adenomatous cancer HT-29 cells

Reyhan Akhtar1, Mohd. Ali2, Safrunnisa Mahmood3 and Sankar Nath Sanyal4

1Department of Pharmacology and 3Department of Experimental Medicine and Biotechnology. Postgraduate Institute of Medical Education and Research. Chandigarh. 2Faculty of Pharmacy. Jamia Hamdard. New Delhi. 4Department of Biophysics. Panjab University. Chandigarh.

Abstract

Background: Silibinin a flavonoid from milk thistle (Silybum marianum) exhibit a variety of pharmacological actions, including anti-proliferative and apoptotic activities against various types of cancers in intact animals and cancer cell lines. In the present study, the effect of silibinin on human colon cancer HT-29 cells was studied.

Method: Incubations of cells with different silibinin concentrations (0.783-1,600 ug/ml) for 24, 48 or 72 h showed a progressive decline in cell viability.

Results: Loss of cell viability was time dependent and optimum inhibition of cell growth (78%) was observed at 72 h. Under inverted microscope, the dead cells were seen as cell aggregates. IC50 (silibinin concentration killing 50% cells) values were 180, 110 and 40ug/ml at 24, 48 and 72 h respectively.

Conclusion: These findings re-enforce the anticancer potential of silibinin, as reported earlier for various other cancer cell lines (Ramasamy and Agarwal (2008), Cancer Letters, 269: 352-62).

(Nutr Hosp. 2014;29:388-392)
DOI:10.3305/nh.2014.29.2.7080

Key words: Colon cancer. HT-29. Proliferation. Silibinin.

Correspondence: Sankar Nath Sanyal.
Department of Biophysics.
Panjab University.
Chandigarh 160014.
India.
E-mail: sanyalpu@gmail.com
Recibido: 25-IX-2013.
1.ª Revisión: 3-X-2013.
Aceptado: 5-XI-2013.
Objectives

Analysis of anti proliferative activity of Silibinin on HT-29 cell line at different time periods

Introduction

Silibinin is a flavonoid, and an active ingredient of milk Thistle (Silybum marianum) extracts. The compound exhibits numerous pharmacological activities1. Silibinin exhibits anti-inflammatory, anti-oxidant and cytotoxic effects in number of studies2. The drug has been used in humans as anti-hepatotoxic agent in the treatment of hepatic carcinoma, Cirrhosis, and as cytotoxic agent against chemotherapeutic side effects in children with acute lymphoblastic lymphoma3-5. FACS (Flourescence activated cell sorter) studies by Agarwal et al.6 have shown elevated expression of cyclin dependent kinase D activity, resulting in cell cycle arrest and apoptosis in colon cancer HT-29 cell line. Inhibition of skin cancer cell growth by silibinin has been reported7. Hogan et al. 8 have shown that silibinin inhibits cell proliferation and causes cell cycle arrest of a number of colon cancer cell lines; namely Fet, Geo and HCT-116. Silibinin is reported to exhibit chemo preventive and chemo therapeutic actions against various types of cancers in animals systems also9-12. Anti-angiogenic properties of silibinin have been described by Yang et al.13 in LoVo colon cancer cell line. Singh et al.14 have reported cancer preventive and therapeutic efficacy of silymarin in animal cancer cell line cultures also.

HT-29 is adenomatous cancer cell line derived human colon. Compared to other cell lines, these cells are more malignant and are frequently used as an experimental model of colon cancer in cell culture. In the present study, the effect of silibinin on the growth of HT-29 cells was investigated in cell culture. These findings suggest that silibinin is a potent inhibitor of the growth of the cells, which produced nearly 80% inhibition of cell viability after 72 h and aggregation of the dead cells in vitro.

Material and Methods

All chemicals used were of analytical grade quality. Silibinin and MTT were procured from Sigma Chemical Co., St.Louis (MO, USA). HT-29 cells were obtained from National Centre for Cell Science (Pune) India.

Abbreviations

DMSO: Dimethyl Sulphoxide.
ELISA: Enzyme linked immune sorbant assay.
FACS: Fluorescence-activated cell sorting.
IC50: Inhibitory Concentration 50.
MTT: 5,(4,5-dimethylthiazole-2-yl)-2, 5 dimethyl tetrazolium bromide.
µg: Microgram.

MTT Assay

MTT cell proliferation assay was performed following the method describe by Noh et al.5 This assay is based on the reduction of tetrazolium salt of MTT to form ultra purple Formozan by the viable cells. 50 µl of the HT-29 cell suspension was placed in 96 well plates at a density of 1X10^6 cells per well and incubated with MTT (5 mg/ml in phosphate buffered saline) in humidiﬁed incubator for 2-3 h. The cells were treated with silibinin dissolved in Dimethylsulfoxide (DMSO) at concentrations of 0.783, 1.56, 3.12, 6.25, 12.5, 25, 50, 100, 200, 400, 800, and 1,600 µg/ml and cell viability was determined at 24, 48 and 72 h by performing MTT [5,(4,5-dimethylthiazole-2-yl)-2, 5 dimethyl tetrazolium bromide] assay.

Results

Figure 1 shows the structure of silibinin molecule, which is a bioactive flavonoid and active ingredient of milk thistle (Silybum marianum).

As shown in figure 2A control cells and figure 2B cells incubated with DMSO appeared well separated...
and normal under the growth conditions. However, the cells grown in presence of silibinin for 24 h showed an aggregated mass of dead cells, at a concentration of 1600 µg/ml of the drug (fig. 2C) under inverted microscope. MTT assay revealed a progressive decline in cell viability with an increase in the drug concentration from 0.783 to 1600 µg/ml (fig. 3). At the highest concentration of silibinin used, 78% of the cells were found dead, while 22% of viable cells were present in the culture well. Similarly, when HT-29 cells were incubated with the drug for 48 h, revealed a large mass of the dead cells, when viewed under microscope (fig. 2D). MTT assay also revealed a steep decline in cell viability, as the drug concentration was increased. At the highest silibinin concentration, 73% of the cells were killed, while 27% of viable cells were seen under these conditions (fig. 3).

HT-29 cells, when incubated in presence of the different concentrations of silibinin for 72 h showed a larger mass of the aggregated dead cells (fig. 2E). The cell proliferation and viability as determined by MTT assay revealed a decline in cell viability as the drug concentration was increased from 0 to 1600 µg/ml in the culture medium. At the highest concentration of silibinin used, 78% of the cells were recorded as dead, while 22% of viable cells were observed under these conditions (fig. 3). Silibinin concentration, which inhibited 50% of the cells (IC50) values were determined from the data presented in figure 3. As shown in table I, cells incubated with silibinin for 24 h showed IC50 value of 180 µg/ml, which was further reduced to 110 µg/ml for HT-29 cells incubated with the drug for 48 h. The value of IC50 for cells incubated with silibinin for 72 h was 40 µg/ml under these conditions. These results show that efficacy of the drug in killing HT-29 cells in vitro was markedly enhanced with time when the cells were allowed to be in contact with silibinin up to 72 h.

**Discussion**

Interest in the use of naturally occurring compounds as chemopreventive agents for carcinogenesis has been on the rise in recent years since a variety of fruits, vegetables and phytochemicals offer high anti-cancer efficacy and low toxicity to normal tissues. Silibinin is one such compound, which has strong anti-proliferative activity against various cancer cell lines. In the present study, MTT assay was used to determine cell viability in the absence and presence of different concentrations of silibinin using HT-29 cells. The data, presented herein show, that viability of the cells was reduced by over 72% in presence of silibinin, after 24-72 h. These results in general are in agreement to
earlier studies of Agarwal et al., who reported cell-cycle arrest and apoptosis of the colon cancer cells. Similar to earlier reports, the potency of silibinin to inhibit cell growth was augmented with increase in time the cells were allowed to interact with the drug. Although Silibinin inhibits the growth of a number of cancer cell lines in vitro, but the degree of inhibition varies with severity of the carcinogenicity. Present data show, IC50 values for HT-29 cells was 40 ug/ml at 72 h, whereas other investigators reported IC50 values of 75 ug/ml for HT-29 cells using FACS analysis (4), 150 uM for bladder papilloma RT4 cells (5), and 5 ug/ml for FET cells and GEO cells and 38 ug/ml for HT116 cells. Noh et al. have reported IC50 value for silibinin in MCF-7 human breast cancer cells. Thus, the efficacy of silibinin in inhibiting the growth of different cancer lines is quite different. Such differences in the potency of the drug in arresting cell growth may be due to differences in the experimental conditions used, the cell type and potential carcinogenicity of the cell lines.

Although the underlying mechanism by which silibinin inhibits the cell growth of cancer lines is essentially unknown. But it was apparent, that the dead cells produced an aggregated massive cell mass. Agarwal et al. have reported the up regulation of certain cell cycle bio-markers, such as Kopl/p27 and Cipl/p21 proteins, as well as the mRNA levels encoding these proteins. However, a decrease in the expression of CDK2 and CDK4, cyclin E and Cyclin D1 proteins was also observed. It was reported that 15% of the cells showed apoptotic cell death after 48 h of silibinin treatment of the cells. Present data showed 78% of the cells died after 72 h, when incubated with 1,600 ug/ml of silibinin. The apparent discrepancy in the two studies may be attributed to different concentration of the drug used in the two studies (100 versus 1,600 µg/ml).

Hogan et al. have described that silibinin markedly inhibited the cell proliferation by causing cell cycle arrest, which involved a decrease in CDK expression, which is a fundamental cell cycle regulatory protein.
The effect of silibinin was more potent in HCT116 cells, which exhibit more malignancy compared to FET and GEO cancer cell lines. Inhibition of human prostate cancer PC-3 tumour xenograft in athymic nude mice by silibinin treatment has also been reported by Singh et al.\textsuperscript{10} The observed decrease in tumour growth was associated with reduced Vascular Endothelial Growth Factor (VEGF) expression. An increase in apoptosis of human bladder papilloma RT-4 cancer cells by silibinin has been reported by Tyagi et al.\textsuperscript{17} both in vivo and in vitro conditions. Silibinin exposure elevated the expression of P53 levels in RT-4 cells and increased phosphorylation of ser-15 activated caspase cascade and caused bid cleavage for apoptosis. Enhanced apoptosis of MCF-7 human breast cancer cells in presence of silibinin has been described by Noh et al.\textsuperscript{11}. A 60% decrease in cell viability was observed by these investigators in presence of 200 µM silibinin. Silibinin has been reported to exhibit strong anti-oxidant activity in intact animal systems\textsuperscript{2}. This property of the compound could be the underlying basis of its anti-tumour activity in a variety of cancer cell lines, including HT-29 cells, as shown in the present study. Hadi et al.\textsuperscript{19} have proposed that anti-cancer property of plant polyphenols involves the arrest of cell-cycle by inducing cyclin A and E and inactivation of cell cycle regulator cdc2. It was shown that polyphenols with anti-cancer and pro-apoptotic properties are able to sequester the endogenous copper ions in the nucleus, which lead to an inter-nucleosome DNA breakage, since such regions of DNA are more labile to cleavage by reactive oxygen species (ROS).

In conclusion, the present findings support the earlier anticancer properties of silibinin that has great potential in inhibiting the growth of HT-29 cancer cells in vitro. The drug could be useful as a potential chemo preventive and therapeutic agent in the treatment of colon cancer.

References